Research
Hormonal
GLP-1 receptor agonists promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity.
GLP-1 receptor agonists can be considered for managing type 2 diabetes and obesity in clinical practice.
StrongSupportsmedium confidence
Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity.
Why this rating
Based on large-scale randomized, controlled trials mentioned in the abstract.
Source
GLP-1 Receptor Agonists
Clifford J. Rosen et al. · New England Journal of Medicine · 2026
DOI 10.1056/nejmra2500106
reviewCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →